SCHEMBL20147684

SCHEMBL20147684

CC(C)N1CCC(C)(NC(=O)Cc2ccccc2)C1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 4/20 0.46
▸ CCR1 P32246 2/20 0.45
▸ LMNA P02545 1/20 0.43
▸ DPP4 P27487 1/20 0.42
▸ CTSL P07711 1/20 0.41
▸ SIGMAR1 Q99720 1/20 0.41
▸ HTT P42858 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ APAF1 O14727 1/20 0.41
▸ TDP2 O95551 1/20 0.41
▸ NSD2 O96028 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ KDM4C Q9H3R0 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ ADRB2 P07550 1/20 0.41
▸ HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20147687 0.92 CNR2 (0.48) CNR2CCR1LMNADPP4CTSL
SCHEMBL20068818 0.83 NPC1 (0.46) CCR1DPP4SIGMAR1HTTKDM4E
SCHEMBL25504736 0.81 MEN1 (0.48) DPP4SIGMAR1HTTKDM4EAPAF1
SCHEMBL20152063 0.80 ATM (0.47) CCR1CTSLHTTMAPTALDH1A1
SCHEMBL20068820 0.80 NPC1 (0.51) DPP4SIGMAR1HTTKDM4EAPAF1
SCHEMBL17033023 0.79 MEN1 (0.53) CNR2LMNACTSLSIGMAR1HTT
SCHEMBL21465972 0.77 HSD11B1 (0.54) DPP4SIGMAR1HTTPOLBKDM4E
SCHEMBL20069745 0.76 P2RX7 (0.46) CCR1POLBMAPTALDH1A1
SCHEMBL20147537 0.73 GAA (0.43) DPP4HTTPOLBMAPTALDH1A1
SCHEMBL5862098 0.73 SIGMAR1 (0.67) SIGMAR1POLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 — — US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 — — US disclosed
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 — — US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 — — US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CNR2 4423/4885CCR1 1283/4885LMNA 1968/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CNR2 4423/4885CCR1 1283/4885LMNA 1968/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CNR2 4423/4885CCR1 1283/4885LMNA 1968/4885
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CNR2 4423/4885CCR1 1283/4885LMNA 1968/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CNR2 4423/4885CCR1 1283/4885LMNA 1968/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 CNR2 4423/4885CCR1 1283/4885LMNA 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback